New Delhi, 27th November 2025: Health Biotech Limited (Health Biotech), a research-driven pharmaceutical manufacturer from India made a strong impact at CPHI India 2025, held at the India Expo Mart (IEML), Knowledge Park II, Greater Noida, Delhi NCR. As one of the most prominent platforms for the global pharmaceutical industry, the event brought together industry leaders, innovators, and partners from across continents.
At the exhibition, Health Biotech received an enthusiastic response from visitors, including international business delegates and sourcing partners. The company’s wide product portfolio and advanced manufacturing capabilities showcased at the event attracted significant attention-reinforcing Health Biotech’s reputation as a trusted, quality-centric pharmaceutical manufacturer.
Speaking at the event, Mr. Parmjit Arora, Managing Director, Health Biotech Limited said: “CPHI India offers a powerful platform to engage with partners who share our commitment to innovation, quality, and global healthcare advancement. Our participation reflects the consistent progress we have made in expanding research-led manufacturing and specialty formulations. From oncology injectables to critical care, anaesthetic solutions, and advanced drug delivery systems, every collaboration strengthens our mission to make reliable and affordable medicines accessible worldwide.”
Mr. Amrit Arora, Director, Health Biotech Limited, was also present, engaging with domestic and international partners.
Health Biotech is widely recognized for developing and manufacturing high-quality, cost-effective generics and specialty pharmaceuticals. Its core expertise lies in injectables including lyophilized, liquid, dry powder, and liposomal forms-along with pre-filled syringes, ampoules, vials, ophthalmic drops, sterile ointments, and syrups. This diverse sterile and non-sterile portfolio positions the company among India’s few end-to-end formulation specialists.
The company’s WHO-GMP and ISO 9001:2008 certified manufacturing facility is located in the Baddi industrial belt in Himachal Pradesh, equipped with cutting-edge technologies such as auto-tunnel sterilization, lyophilization systems, and form-fill-seal processes for sterile injectables and PFS solutions.
Since commencing operations in 2005, Health Biotech has evolved into a reliable contract manufacturing partner for leading pharmaceutical companies including Cipla, Cadila, Piramal, Vetoquinol, and Lupin. The company has expanded its manufacturing footprint to over 100,000 square feet, supporting a rapidly growing portfolio of innovative and globally compliant products.
In 2009, Health Biotech began its own domestic and international marketing journey. Alongside this, it established a Government of India-approved R&D Centre, focusing on nano-particle and liposomal drug delivery systems, plant-based research, and bio-waste utilization. Notable projects include the purification of heparin from bio-waste and the development of recombinant Darbepoetin Alfa.
Today, Health Biotech manufactures close to 1,000 pharmaceutical products across key therapeutic segments including oncology, hormones, critical care, and higher antibiotics, further solidifying its leadership in specialized formulations and complex injectables.
Health Biotech’s participation in CPHI India 2025 at IEML demonstrated its commitment to global standards, meaningful partnerships, and healthcare innovation. The overwhelming response at the event underscores the industry’s confidence in Health Biotech’s consistent quality, niche expertise, and scientific excellence.
